Lot 87 King's Legacy (AUS) – My Chicharita (NZ), Chestnut Gelding

NZB Ready To Run Sale 2024

  • Lot 87 King's Legacy (AUS) – My Chicharita (NZ), Chestnut Gelding
  • Lot 87 King's Legacy (AUS) – My Chicharita (NZ), Chestnut Gelding

Born

30 Aug 2022

$190,000.00

60% Available

Email About This HorseFill our Enquiry Form

Description

Lot 87 ch. g. King’s Legacy – My Chicharita (Towkay) $190,000 (draft: Kilgravin Lodge)

From the first crop of Coolmore Stud stallion and dual Group One winner King’s Legacy (Redoute’s Choice), he displayed good balance and stretch in his breeze up in October at Te Rapa.

After being purchased as a yearling for $1.4m at Magic Millions on the Gold Coast, King’s Legacy, by Champion Sire Redoute’s Choic (Danehill), was a dual Group One winning two-year-old in the Inglis Sires Stakes (Gr. 1, 1400m) and Champagne Stakes (Gr. 1, 1600m).

Hi dam, My Chicharita, was trained at Matamata, winning three races to 2000m including the prestigious Royal Stakes (Gr. 2, 2000m) and proven as a broodmare with three individual winners of 13 races from 1000m to 2000m, showing good versatility.

A gem in any pedigree, grand-dam Trisynd, a winner over 2140 metres, is by breeding shaping Champion Sire Sir Tristram, whose sons Zabeel, and in turn Savabeel, have been mainstays in the New Zealand breeding industry.

Trisynd left four individual winners of 10 races, including Group Two winner My Chicharita, the dam of this gelding.

Continuing the strength of stakes winners in the family, third dam Swiftsynd (Swift Gun) was a Group Three winner among nine victories, before going on to leave six winners of 19 races.

“We bought two yearlings by this promising stallion at the yearling sales this year at Karaka, and they’ve shown a lot in the stable,” said David Ellis.

“Both trialed in October at Matamata, with Born To Be Royal winning stylishly and Queen’s Evidence sustaining a good effort for third.

“He’s a good moving horse, breezed up well, and we liked everything about him. He’s strong, out of a good mare, and we’re obviously quite bullish about the stallion.” 

Pricing of shares includes sale expenses, pedigree analysis and research at cost, and full veterinary and x-ray examinations. Insurance additional.

You Might Also Be Interested In

Enquire Now

Sign up to our newsletter